Live
- Deepika Padukone delights with pregnancy photoshoot
- Employ behaviour change strategies for eradicating malnutrition: Guv
- BJP Shares Video Of TMC MLA Lovely Maitra Allegedly Comparing Doctors To Butchers Amid Ongoing Protests
- Jr. NTR and Vishwak Sen Contribute to Flood Relief Efforts in Telugu States
- Prakasam Barrage Flow Reduces After Record Flood Levels
- Vivo T3 Pro 5G Debut Today: Price, First Sale Offers and Specifications
- Medical camp held on Pawan Kalyan’s birthday
- CBI Arrests Ex-Principal Of RG Kar Medical College Amid Financial Misconduct Allegations
- BJP criticises restriction on Tirumala laddu
- Harish Rao slams CM for politicising crisis
Zydus gets final approval from US FDA for Type 2 diabetes pills
Indian pharma company Zydus Lifesciences on Friday said that it has received final approval from the US Food and Drug Administration (USFDA) to market tablets for Type 2 diabetes.
Ahmedabad: Indian pharma company Zydus Lifesciences on Friday said that it has received final approval from the US Food and Drug Administration (USFDA) to market tablets for Type 2 diabetes.
The drugmaker said it got “approval for its New Drug Application (NDA) to market Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets”.
With this, Zydus has all three NDAs of Sitagliptin (base) and combination franchise approved, it added.
"Notably, all the three NDAs achieved first-cycle approval (FCA)," the company stated.
Further, it added that the product will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India.
According to IQVIA (MAT May 2024), the US market for DPP-IV inhibitors and its combinations is $9.5 bn.
